These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis. Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493 [TBL] [Abstract][Full Text] [Related]
3. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849 [TBL] [Abstract][Full Text] [Related]
4. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer. Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169 [TBL] [Abstract][Full Text] [Related]
5. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341 [TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495 [TBL] [Abstract][Full Text] [Related]
7. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Cappelli LC; Brahmer JR; Forde PM; Le DT; Lipson EJ; Naidoo J; Zheng L; Bingham CO; Shah AA Semin Arthritis Rheum; 2018 Dec; 48(3):553-557. PubMed ID: 29573850 [TBL] [Abstract][Full Text] [Related]
8. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer. Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M; J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586 [TBL] [Abstract][Full Text] [Related]
9. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. Verspohl SH; Holderried T; Behning C; Brossart P; Schäfer VS Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006963. PubMed ID: 33912248 [TBL] [Abstract][Full Text] [Related]
10. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis. Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D Front Oncol; 2021; 11():749064. PubMed ID: 34900695 [TBL] [Abstract][Full Text] [Related]
11. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review. Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224 [TBL] [Abstract][Full Text] [Related]
12. Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer. Melia A; Fockens E; Sfumato P; Zemmour C; Madroszyk A; Lafforgue P; Pham T Joint Bone Spine; 2023 Jan; 90(1):105457. PubMed ID: 36116771 [TBL] [Abstract][Full Text] [Related]
13. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases. Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908 [TBL] [Abstract][Full Text] [Related]
14. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors. Gilbert D; Hu J; Medina T; Kessler ER; Lam ET Hum Vaccin Immunother; 2023 Dec; 19(1):2207438. PubMed ID: 37157982 [TBL] [Abstract][Full Text] [Related]
15. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors. Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774 [TBL] [Abstract][Full Text] [Related]
16. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience. Mooradian MJ; Nasrallah M; Gainor JF; Reynolds KL; Cohen JV; Lawrence DP; Miloslavsky EM; Kohler MJ; Sullivan RJ; Schoenfeld SR Semin Arthritis Rheum; 2019 Jun; 48(6):1127-1132. PubMed ID: 30409415 [TBL] [Abstract][Full Text] [Related]
18. Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. Mathias K; Rouhani S; Olson D; Bass AR; Gajewski TF; Reid P Oncologist; 2023 May; 28(5):440-448. PubMed ID: 36595378 [TBL] [Abstract][Full Text] [Related]
19. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors. Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117 [TBL] [Abstract][Full Text] [Related]